Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Accured Expenses (2016 - 2025)

Collegium Pharmaceutical has reported Change in Accured Expenses over the past 10 years, most recently at $10.7 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $10.7 million for Q4 2025, down 52.26% from a year ago — trailing twelve months through Dec 2025 was -$9.5 million (up 75.98% YoY), and the annual figure for FY2025 was -$9.5 million, up 75.98%.
  • Change in Accured Expenses for Q4 2025 was $10.7 million at Collegium Pharmaceutical, up from -$8.1 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for COLL hit a ceiling of $22.4 million in Q4 2024 and a floor of -$62.9 million in Q3 2024.
  • Median Change in Accured Expenses over the past 5 years was -$249500.0 (2022), compared with a mean of -$2.7 million.
  • Peak annual rise in Change in Accured Expenses hit 1635.09% in 2025, while the deepest fall reached 2777.73% in 2025.
  • Collegium Pharmaceutical's Change in Accured Expenses stood at $10.8 million in 2021, then grew by 25.76% to $13.6 million in 2022, then plummeted by 62.42% to $5.1 million in 2023, then surged by 339.04% to $22.4 million in 2024, then tumbled by 52.26% to $10.7 million in 2025.
  • The last three reported values for Change in Accured Expenses were $10.7 million (Q4 2025), -$8.1 million (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.